Écrit par Wiley | 27 Octobre 2014

A new study has found that certain prostate cancer medications are linked with an increased risk of dying from heart-related causes in men with congestive heart failure or prior heart attacks. Published in BJU International, the findings will help doctors and patients weigh the benefits and risks of the drugs.

Androgen deprivation therapy (ADT), which reduces levels of male hormones in...

Écrit par UNN | 17 Octobre 2014

(Livingston, NJ, USA, 15.10.2014 ) The SyncroPatch 384/768PE offers the highest throughput in automated patch clamping history. The SyncroPatch 384/768PE focuses on providing both high quality recordings together with broad experimental versatility, two important hallmarks that clearly convinced scientific researchers at the Northwestern University Feinberg School of Medicine, Chicago...

Écrit par GlobalData | 17 Octobre 2014

LONDON, UK (GlobalData), 16 October 2014 - The global aortic stent grafts market will increase in value from an estimated $1.2 billion in 2013 to just over $1.9 billion by 2020, representing a Compound Annual Growth Rate (CAGR) of 6.7%, according to research and consulting firm GlobalData.

The company’s latest report* states that this growth, which relates to ten major countries, namely...

Écrit par DBV Technologies | 15 Octobre 2014

Bagneux, France, le 14 octobre 2014 - DBV Technologies (Euronext: DBV - ISIN: FR0010417345), créateur de Viaskin®, nouvelle référence dans le traitement de l'allergie, a annoncé aujourd'hui ses produits opérationnels, ainsi que sa situation nette de trésorerie, pour les neuf premiers mois de 2014.



Produits opérationnels pour les neuf premiers mois de 2014

Au cours des neuf...